| 11.03.21 | AbbVie’s Parkin son’s pump hits goal in phase 3; Stallergenes taps Aptar for connected delivery project

Klicken Sie hier, um Fiercebiotech.com zu abonnieren

Laden...

3 jahre vor

Html
Text

Webinar: State of the Art Research Methods for Value-Based Pricing

Wednesday, November 10, 2021 | 12pm ET / 9am PT

In the healthcare industry, innovation is essential. With so many medical products developed and launched daily, pharmaceutical, healthcare services, biotechnology, medical device, diagnostic, and life science companies should clearly understand if products fit the needs of the market. To answer this, you must identify what your customers perceive as valuable. Register now.

Today's Rundown

AbbVie's Parkinson's pump hits goal in phase 3, setting stage for approval filings Stallergenes, seeking an edge in a competitive space, taps Aptar for connected drug delivery project AstraZeneca resumes asset sale in $270M COPD deal with familiar buyer Covis Meissa posts early clinical data on nasal COVID-19 vaccine, providing support for role in breaking transmission chains A COVID-19 vaccine delivered with a patch rivals traditional shots in mice: study

Featured Story

AbbVie's Parkinson's pump hits goal in phase 3, setting stage for approval filings

By Nick Paul Taylor

AbbVie’s bid to cannibalize its own Parkinson’s disease business has advanced, with the phase 3 success of subcutaneous, pump-delivered levodopa-carbidopa formulation ABBV-951 providing the backbone of planned approval filings.

Webinar: The cell therapy divide - How to navigate the challenges of taking clinical-level manufacturing capacity up to commercial scale

Tuesday, November 16 | 11am ET / 8am PT

When your manufacturing process depends on healthcare professionals working with the patients to get the front-end and back-end of the processes exactly right, those professionals need to understand your process unequivocally. We’ll discuss the challenges posed by this new wave of therapies and how the pioneers in the field are tackling them. Register Now.

Stallergenes, seeking an edge in a competitive space, taps Aptar for connected drug delivery project

By Nick Paul Taylor

Stallergenes Greer has identified drug delivery as a way to differentiate its allergen immunotherapies from rival products, leading it to partner with Aptar Pharma to develop a connected device.

AstraZeneca resumes asset sale in $270M COPD deal with familiar buyer Covis

By Angus Liu

Over the years, AstraZeneca has consistently adjusted its portfolio, targeting ageing products. The company has now found a new home for two respiratory meds with an old buyer, which together turned in $143 million in sales last year.

Meissa posts early clinical data on nasal COVID-19 vaccine, providing support for role in breaking transmission chains

By Nick Paul Taylor

Meissa Vaccines has presented early clinical data on its nasal COVID-19 vaccine, revealing the highest dose of the recombinant live attenuated candidate triggered similar nasal antibody levels to natural immunity.

A COVID-19 vaccine delivered with a patch rivals traditional shots in mice: study

By Kyle LaHucik

Researchers at University of Queensland collaborated with Vaxxas to develop a COVID-19 patch that warded off the virus in mice. They hope to raise funding to bring the patch into clinical testing but are facing competition from existing vaccines and other patch developers.

Executive Summary: The Path to Self-Administration: Considerations for Moving from Pre-Filled Syringe to Auto-Injector

There are a number of important considerations for pharmaceutical companies that are considering a move to auto-injector devices. Learn how product characteristics, formulation, and patient needs impact device selection and manufacturing processes – and how experienced partners can help. Download Now.